Assessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma

Basit Öğe Kaydı
dc.authorid0000-0002-0121-5228
dc.authorid0000-0002-0853-4096
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorSozel, Yildiz
dc.contributor.authorOnder, Arif Hakan
dc.date.accessioned2026-01-24T12:29:26Z
dc.date.available2026-01-24T12:29:26Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBACKGROUND: The response of Renal Cell Cancer (RCC) to tyrosine kinase inhibitors (TKI) has been well established. Although these stratifications have been established for TKI response and prognosis, these parameters have recently been used to predict immunotherapy response in RCC. We aimed to use a combination of clinical parameters of International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk groups and metastatic sites at the time of diagnosis to predict the effectiveness of immune checkpoint inhibitors in malignant melanoma (MM). METHOD: In this cross-sectional study, we retrospectively analyzed the demographic information, metastatic sites, and IMDC risk group data. The blood parameters were included in the first cycle of nivolumab treatment. RESULTS: The OS was statistically different between the RCC and MM groups in terms of the IMDC. In univariate analysis of stage at diagnosis, CRP levels and bone and bone marrow metastases were confirmed to be prognostic factors in the MM population in terms of OS. Brain metastasis was a prognostic factor for RCC, whereas sex, line of treatment, LDH, bone, and splenic metastasis remained significant in patients with MM in terms of OS. Brain metastasis was prognostic in both cancer types in multivariate analysis in terms of PFS. In addition to brain metastasis, LDH levels and lung, liver, and splenic metastases also affect PFS in patients with MM undergoing nivolumab treatment. CONCLUSION: In our study, the IMDC was confirmed to be a prognostic factor for MM. The IMDC groups were similar, except for the favorable RCC and MM groups. Different metastatic sites were prognostic, similar to the IMDC risk group in the MM group.
dc.identifier.doi10.3233/CBM-230159
dc.identifier.endpage377
dc.identifier.issn1574-0153
dc.identifier.issn1875-8592
dc.identifier.issue3
dc.identifier.pmid37718781
dc.identifier.scopus2-s2.0-85177504350
dc.identifier.scopusqualityQ2
dc.identifier.startpage367
dc.identifier.urihttps://doi.org/10.3233/CBM-230159
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5358
dc.identifier.volume38
dc.identifier.wosWOS:001099630200009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherIos Press
dc.relation.ispartofCancer Biomarkers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectIMDC risk group
dc.subjectmalign melanoma
dc.subjectImmunotherapy
dc.subjectnivolumab
dc.subjectmetastatic sites
dc.subjectrenal cell carcinoma
dc.titleAssessing the prognostic value of IMDC risk score for nivolumab-treated patients with renal cancer and malignant melanoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu